R.A. Session II - Mar 6, 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
10%+ Owner
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Mar 6, 2023
Transactions value $
$0
Form type
4
Date filed
3/8/2023, 06:38 PM
Previous filing
Dec 23, 2022
Next filing
Jun 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Other $0 +251K +2.74% $0.00 9.42M Mar 6, 2023 Direct F1, F2, F3
holding TSHA Common Stock 141K Mar 6, 2023 See footnote F4
holding TSHA Common Stock 141K Mar 6, 2023 See footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Disposed to Issuer -200K -100% 0 Mar 6, 2023 Common Stock 200K $1.95 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors (the "RSU Award"). The RSU Award replaced a prior stock option award of 199,500 shares of similar value that was canceled effective March 6, 2023.
F2 Each share is represented by an RSU. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs are fully vested.
F3 In connection with the Reporting Person's separation from the Issuer, the Reporting Person forfeited 21,374 unvested shares pursuant to a restricted stock award.
F4 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
F5 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.
F6 Prior to the cancellation of this option, 25% of the total number of shares underlying the option were to vest and become exercisable on November 10, 2023 and the remainder were to vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F7 This option was canceled by mutual agreement of the Issuer and the Reporting Person. The Reporting Person received the RSU Award in exchange for the cancellation of this option.